CVE-2009-3629

Description

Multiple cross-site scripting (XSS) vulnerabilities in the Backend subcomponent in TYPO3 4.0.13 and earlier, 4.1.x before 4.1.13, 4.2.x before 4.2.10, and 4.3.x before 4.3beta2 allow remote authenticated users to inject arbitrary web script or HTML via unspecified vectors.

Category

3.5
CVSS
Severity: Low
CVSS 2.0 •
EPSS 0.29%
Vendor Advisory secunia.com Vendor Advisory typo3.org Vendor Advisory vupen.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://exchange.xforce.ibmcloud.com/vulnerabilities/53918 vdb entry
http://typo3.org/teams/security/security-bulletins/typo3-sa-2009-016/ vendor advisory
http://secunia.com/advisories/37122 third party advisory vendor advisory
http://marc.info/?l=oss-security&m=125633199111438&w=2 mailing list
http://marc.info/?l=oss-security&m=125632856206736&w=2 mailing list
http://www.vupen.com/english/advisories/2009/3009 vdb entry vendor advisory
http://www.securityfocus.com/bid/36801 vdb entry

Frequently Asked Questions

What is the severity of CVE-2009-3629?
CVE-2009-3629 has been scored as a low severity vulnerability.
How to fix CVE-2009-3629?
To fix CVE-2009-3629, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2009-3629 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2009-3629 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.